Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope

Brooks, Nicole; Hsu, Jennifer L.; Esparon, Sandra; Pouniotis, Dodie; Pietersz, Geoffrey A.

doi:10.3390/molecules23092233

Cited by 16 publications

(11 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…tetanus toxoid or tetanus-diphtheria vaccine). 250,365,366 Additional combinatorial partners for DC-based vaccines in clinical development include: (1) standard-of-care neoadjuvant chemotherapy based on ICD inducers like cyclophosphamide or non-ICD inducers like temozolomide and decitabine; 291,367 (2) radiotherapy; 368 or (3) targeted therapies (e.g. the tyrosine kinase inhibitor axitinib).…”

Section: Ongoing Clinical Trialsmentioning

confidence: 99%

Trial watch: dendritic cell vaccination for cancer immunotherapy

et al. 2019

View full text Add to dashboard Cite

Dendritic-cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumorassociated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immunooncology.

show abstract

Section: Ongoing Clinical Trialsmentioning

confidence: 99%

Trial watch: dendritic cell vaccination for cancer immunotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Brooks et al . chemically synthesized tripartite peptide (AntpMUC1tet), which consists of a penetratin, a single variable number of tandem repeat of the mucin 1 (MUC1) antigen and a tetanus toxoid universal CD4 T helper epitope peptide (tetCD4) [105]. MUC1 is a type I transmembrane glycoprotein, and have been widely used as targets for cancer vaccines [106].…”

Section: Applications Of Cpps In Vaccine Deliverymentioning

confidence: 99%

Cell-penetrating Peptides: Efficient Vectors for Vaccine Delivery

Yang

Luo

Shibu

et al. 2019

CDD

View full text Add to dashboard Cite

Subunit vaccines are composed of pathogen fragments that, on their own, are generally poorly immunogenic. Therefore, the incorporation of an immunostimulating agent, e.g. adjuvant, into vaccine formulation is required. However, there are only a limited number of licenced adjuvants and their immunostimulating ability is often limited, while their toxicity can be substantial. To overcome these problems, a variety of vaccine delivery systems have been proposed. Most of them are designed to improve the stability of antigen in vivo and its delivery into immune cells. Cell-penetrating peptides (CPPs) are especially attractive component of antigen delivery systems as they have been widely used to enhance drug transport into the cells. Fusing or co-delivery of antigen with CPPs can enhance antigen uptake, processing and presentation by antigen presenting cells (APCs), which are the fundamental steps in initiating an immune response. This review describes the different mechanisms of CPP intercellular uptake and various CPP-based vaccine delivery strategies.

show abstract

“…This year, Brooks et al’s work highlighted the therapeutic potential of a CPP linked to mucin-1 and T-cell epitopes. In a tumor vaccination model, this peptide induces multiple immune responses and delays mucin-1 tumors in mice [ 85 ]. In the same period, Shahbazi and Bolhassani performed a comparison of six cell penetrating peptides for the delivery of HPV16 E7 antigen in the context of HPV.…”

Section: Cpps As Molecular Carriers In Cancermentioning

confidence: 99%

Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies

2019

View full text Add to dashboard Cite

Cell-penetrating-peptides (CPPs) are small amino-acid sequences characterized by their ability to cross cellular membranes. They can transport various bioactive cargos inside cells including nucleic acids, large proteins, and other chemical compounds. Since 1988, natural and synthetic CPPs have been developed for applications ranging from fundamental to applied biology (cell imaging, gene editing, therapeutics delivery). In recent years, a great number of studies reported the potential of CPPs as carriers for the treatment of various diseases. Apart from a good efficacy due to a rapid and potent delivery, a crucial advantage of CPP-based therapies is the peptides low toxicity compared to most drug carriers. On the other hand, they are quite unstable and lack specificity. Higher specificity can be obtained using a cell-specific CPP to transport the therapeutic agent or using a non-specific CPP to transport a cargo with a targeted activity. CPP-cargo complexes can also be conjugated to another moiety that brings cell- or tissue-specificity. Studies based on all these approaches are showing promising results. Here, we focus on recent advances in the potential usage of CPPs in the context of cancer therapy, with a particular interest in CPP-mediated delivery of anti-tumoral proteins.

show abstract

Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope

Cited by 16 publications

References 69 publications

Trial watch: dendritic cell vaccination for cancer immunotherapy

Trial watch: dendritic cell vaccination for cancer immunotherapy

Cell-penetrating Peptides: Efficient Vectors for Vaccine Delivery

Recent Advances in Cell Penetrating Peptide-Based Anticancer Therapies

Contact Info

Product

Resources

About